BR112012022338A2 - anticorpos monoclonais direcionados a cd20 - Google Patents

anticorpos monoclonais direcionados a cd20

Info

Publication number
BR112012022338A2
BR112012022338A2 BR112012022338A BR112012022338A BR112012022338A2 BR 112012022338 A2 BR112012022338 A2 BR 112012022338A2 BR 112012022338 A BR112012022338 A BR 112012022338A BR 112012022338 A BR112012022338 A BR 112012022338A BR 112012022338 A2 BR112012022338 A2 BR 112012022338A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
canine
targeted
targeted monoclonal
antibodies
Prior art date
Application number
BR112012022338A
Other languages
English (en)
Portuguese (pt)
Inventor
Hansen Genevieve
Original Assignee
Vet Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vet Therapeutics Inc filed Critical Vet Therapeutics Inc
Publication of BR112012022338A2 publication Critical patent/BR112012022338A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112012022338A 2010-03-04 2011-03-04 anticorpos monoclonais direcionados a cd20 BR112012022338A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31044010P 2010-03-04 2010-03-04
PCT/US2011/000415 WO2011109108A1 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to cd20

Publications (1)

Publication Number Publication Date
BR112012022338A2 true BR112012022338A2 (pt) 2017-02-14

Family

ID=44542488

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022338A BR112012022338A2 (pt) 2010-03-04 2011-03-04 anticorpos monoclonais direcionados a cd20

Country Status (6)

Country Link
EP (1) EP2542262A4 (enExample)
JP (2) JP5911813B2 (enExample)
AU (2) AU2011221553B2 (enExample)
BR (1) BR112012022338A2 (enExample)
CA (1) CA2791560A1 (enExample)
WO (1) WO2011109108A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US9790280B2 (en) * 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
EP3416984B1 (en) 2016-02-18 2021-03-31 Elanco US Inc. Chimeric canine anti-cd20 antibody
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
WO2024158001A1 (ja) 2023-01-25 2024-08-02 日本全薬工業株式会社 イヌのｂ細胞リンパ腫の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
ATE365539T1 (de) 1999-12-30 2007-07-15 Dana Farber Cancer Inst Inc Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
WO2004043344A2 (en) * 2002-11-07 2004-05-27 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
US20080299546A1 (en) * 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
WO2006007202A2 (en) * 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
US8337842B2 (en) 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies

Also Published As

Publication number Publication date
CA2791560A1 (en) 2011-09-09
WO2011109108A1 (en) 2011-09-09
EP2542262A4 (en) 2014-02-26
AU2011221553B2 (en) 2016-05-26
AU2011221553A1 (en) 2012-10-25
AU2016216710A1 (en) 2016-09-08
JP5911813B2 (ja) 2016-04-27
EP2542262A1 (en) 2013-01-09
JP2013520990A (ja) 2013-06-10
JP2016179978A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
BR112012022338A2 (pt) anticorpos monoclonais direcionados a cd20
BR112012022342A2 (pt) anticorpos monoclonais dirigidos a cd52
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX2024012304A (es) Anticuerpos anti-il31 para uso veterinario
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
WO2013063186A3 (en) Monoclonal antibodies and methods of use
EA201300978A1 (ru) Антитела к сеа
EA201891641A1 (ru) Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
PL3181581T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112013028523A8 (pt) Uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
EA201391342A1 (ru) Cd37-связывающие молекулы и их иммуноконъюгаты
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa)
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019.